Amit Parhar
Laggard Clinical Trial Recruitment? Data-first Teams Can Fix It
Recruitment remains the weakest link in any clinical trial. For all the industry talk ...
Building a CAP/CLIA-compliant NGS pipeline: A Technical Blueprint for Diagnostic Labs
In clinical genomics, the labs that scale fastest are not necessarily the ones with the ...
Multi-omics Explained: How Integrating Genomics, Proteomics, and Metabolomics Transforms Disease Understanding
When a cancer cell escapes therapy, it rarely relies on one rogue mutation. It rewires ...
What Is cfDNA? A Beginner’s Guide to Liquid Biopsy and Cell-free DNA Analysis
Imagine diagnosing cancer with a routine blood draw — no surgery, no tissue biopsy, and ...
How Multi-omics, AI, and Real-world Evidence Are Accelerating Biomarker Discovery
"The right biomarker doesn’t just describe disease – it determines destiny." More data ...
Designing Patient-centric Rare-disease Trials with AI, Digital Health, and Multi-omics
Peter Drucker, the renowned Austrian-American consultant and educator, famously said, ...
From Sequencer to Tumor Board: How AI-powered Genomics Platforms Are Rewriting Cancer Diagnosis and Treatment
Cancer care is undergoing a profound shift. What once took weeks of manual interpretation ...
Audit-ready, Cloud-native NGS Pipelines: Ending the Rare Disease Diagnostic Odyssey with Reproducible Science
Did you know that an average rare disease patient spends nearly five years searching for ...
AI-powered Germline Variant Interpretation: Transforming Rare Disease Diagnosis in the Era of Precision Medicine
For rare-disease patients, the diagnostic journey often stretches beyond six years and ...
How NGS and Machine Learning Are Driving 90%+ Diagnostic Performance in Lung Cancer
Global and national epidemiology shows lung cancer remains the leading cause of cancer ...
From Silos to Seamless: How API-first Ecosystems Are Redefining Genomics & Healthcare IT
The success metrics for genomics and healthcare IT projects have undergone significant ...
Reimagining Rare Disease Diagnosis with GenAI: ClairLabs’ Vision for the Future of Precision Medicine
Rare diseases account for nearly 5% of the global disease burden. With the advent of ...
